FDA clears 1st treatment for pancreatic cancer in 30 years, approving Optune Pax to improve survival with chemotherapy.
A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G.
Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.
The FDA has approved a first-of-its-kind portable, noninvasive device that delivers alternating electrical fields for the treatment of locally advanced pancreatic cancer.Optune Pax (Novocure) releases ...
Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.
The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in ...
The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a ...
A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results